FMP
Protagenic Therapeutics, Inc.
PTIX
NASDAQ
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
0.388 USD
-0.0304 (-7.84%)
PTIX Financial Statements
Year
2024
2023
2022
2021
Total Revenue
0
0
0
0
Cost of Revenue
0
28.22k
30
0
Gross Profit
0
-28.22k
-30
0
Operating Expenses
5.7M
4.53M
3.56M
4.14M
Research and Development
3.84M
3.32M
1.59M
1.14M
Selling, General & Administrative Expenses
1.76M
1.21M
1.97M
3M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
1.76M
1.21M
1.97M
3M
Other Expenses
97.36k
0
0
0
Operating Income
-5.7M
-4.53M
-3.56M
-4.14M
Total Other Income/Expenses Net
175.61k
-473.52k
2.28k
-382.52k
Income Before Tax
-5.53M
-5M
-3.56M
-4.52M
Income Tax
0
0
46.05k
463.7k
Net Income
-5.53M
-5M
-3.6M
-4.99M
Basic EPS
-1.13
-1.15
-0.83
-1.35
EPS Diluted
-1.13
-1.15
-0.83
-1.35
Basic Average Shares
4.9M
4.34M
4.32M
3.69M
Diluted Average Shares
4.9M
4.34M
4.32M
3.69M
EBITDA
-5.7M
-4.5M
-3.42M
-4.14M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-30.78M
-25.78M
-22.22M
-17.7M
Net Income
-5.53M
-5M
-3.6M
-4.99M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-36.3M
-30.78M
-25.78M
-22.22M
Other Distributions
-5.53M
-5M
-3.56M
-4.52M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
0
123.33k
1.77k
0
Annual Depreciation
0
28.22k
30
286
Capital Expenditure
0
-149.78k
-1.8k
0
Net PPE
0
244.89k
3.55k
-286
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
